PKA knockdown enhances cell killing in response to radiation and androgen deprivation

Harvey H. Hensley, Jean Michel Hannoun-Levi, Paul Hachem, Zhaomei Mu, Radka Stoyanova, Li Yan Khor, Sudhir Agrawal, Alan Pollack

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

The therapeutic efficacy of GemÂ231, a second generation antisense molecule targeted to the RIα subunit of PKARIα (AS-PKA), administered in combination with androgen deprivation (AD) and radiation therapy (RT), was examined in androgen sensitive (LNCaP) and insensitive (PC3) cell lines. Apoptosis was assayed by Caspase 3 + 7 activity and Annexin V binding. AS-PKA significantly increased apoptosis in vitro from RT (both lines), with further increases in LNCaP cells grown in AD medium. In LNCaP cells, AD increased phosphorylated mitogen activated protein-kinase (pMAPK), which was reduced by AS-PKA relative to the mismatch (MM) controls. AS-PKA also reduced pMAPK levels in PC3 cells. Cell death was measured by clonogenic survival assays. In vivo, LNCaP cells were grown orthotopically in nude mice. Tumor kinetics were measured by magnetic resonance imaging and serum prostate-specific antigen. PC3 cells were grown subcutaneously and tumor volume assessed by caliper measurements. In PC3 xenografts, AS-PKA caused a significant increase in tumor doubling time relative to MM controls as a monotherapy or in combination with RT. In orthotopic LNCaP tumors, AS-PKA was ineffective as a monotherapy; however, it caused a statistically significant increase in tumor doubling time relative to MM controls when used in combination with AD, with or without RT. PKARIα levels in tumors were quantified via immunohistochemical (IHC) staining and image analysis. IHC measurements in LNCaP cells exhibited that AS-PKA reduced PKARIα levels in vivo. We demonstrate for the first time that AS-PKA enhances cell killing androgen sensitive prostate cancer cells to AD ± RT and androgen insensitive cells to RT.

Original languageEnglish
Pages (from-to)962-973
Number of pages12
JournalInternational Journal of Cancer
Volume128
Issue number4
DOIs
StatePublished - Feb 15 2011

Fingerprint

Androgens
Radiation
Radiotherapy
Neoplasms
Mitogen-Activated Protein Kinases
Apoptosis
Caspase 7
Annexin A5
Prostate-Specific Antigen
Tumor Burden
Heterografts
Nude Mice
Caspase 3
Prostatic Neoplasms
Cell Death
Magnetic Resonance Imaging
Staining and Labeling
Cell Line
Serum

Keywords

  • androgen deprivation
  • antisense
  • prostate cancer
  • protein kinase A
  • radiation

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

PKA knockdown enhances cell killing in response to radiation and androgen deprivation. / Hensley, Harvey H.; Hannoun-Levi, Jean Michel; Hachem, Paul; Mu, Zhaomei; Stoyanova, Radka; Khor, Li Yan; Agrawal, Sudhir; Pollack, Alan.

In: International Journal of Cancer, Vol. 128, No. 4, 15.02.2011, p. 962-973.

Research output: Contribution to journalArticle

Hensley, Harvey H. ; Hannoun-Levi, Jean Michel ; Hachem, Paul ; Mu, Zhaomei ; Stoyanova, Radka ; Khor, Li Yan ; Agrawal, Sudhir ; Pollack, Alan. / PKA knockdown enhances cell killing in response to radiation and androgen deprivation. In: International Journal of Cancer. 2011 ; Vol. 128, No. 4. pp. 962-973.
@article{646824def29c4be292aef0761460a0fd,
title = "PKA knockdown enhances cell killing in response to radiation and androgen deprivation",
abstract = "The therapeutic efficacy of Gem{\^A}231, a second generation antisense molecule targeted to the RIα subunit of PKARIα (AS-PKA), administered in combination with androgen deprivation (AD) and radiation therapy (RT), was examined in androgen sensitive (LNCaP) and insensitive (PC3) cell lines. Apoptosis was assayed by Caspase 3 + 7 activity and Annexin V binding. AS-PKA significantly increased apoptosis in vitro from RT (both lines), with further increases in LNCaP cells grown in AD medium. In LNCaP cells, AD increased phosphorylated mitogen activated protein-kinase (pMAPK), which was reduced by AS-PKA relative to the mismatch (MM) controls. AS-PKA also reduced pMAPK levels in PC3 cells. Cell death was measured by clonogenic survival assays. In vivo, LNCaP cells were grown orthotopically in nude mice. Tumor kinetics were measured by magnetic resonance imaging and serum prostate-specific antigen. PC3 cells were grown subcutaneously and tumor volume assessed by caliper measurements. In PC3 xenografts, AS-PKA caused a significant increase in tumor doubling time relative to MM controls as a monotherapy or in combination with RT. In orthotopic LNCaP tumors, AS-PKA was ineffective as a monotherapy; however, it caused a statistically significant increase in tumor doubling time relative to MM controls when used in combination with AD, with or without RT. PKARIα levels in tumors were quantified via immunohistochemical (IHC) staining and image analysis. IHC measurements in LNCaP cells exhibited that AS-PKA reduced PKARIα levels in vivo. We demonstrate for the first time that AS-PKA enhances cell killing androgen sensitive prostate cancer cells to AD ± RT and androgen insensitive cells to RT.",
keywords = "androgen deprivation, antisense, prostate cancer, protein kinase A, radiation",
author = "Hensley, {Harvey H.} and Hannoun-Levi, {Jean Michel} and Paul Hachem and Zhaomei Mu and Radka Stoyanova and Khor, {Li Yan} and Sudhir Agrawal and Alan Pollack",
year = "2011",
month = "2",
day = "15",
doi = "10.1002/ijc.25634",
language = "English",
volume = "128",
pages = "962--973",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "4",

}

TY - JOUR

T1 - PKA knockdown enhances cell killing in response to radiation and androgen deprivation

AU - Hensley, Harvey H.

AU - Hannoun-Levi, Jean Michel

AU - Hachem, Paul

AU - Mu, Zhaomei

AU - Stoyanova, Radka

AU - Khor, Li Yan

AU - Agrawal, Sudhir

AU - Pollack, Alan

PY - 2011/2/15

Y1 - 2011/2/15

N2 - The therapeutic efficacy of GemÂ231, a second generation antisense molecule targeted to the RIα subunit of PKARIα (AS-PKA), administered in combination with androgen deprivation (AD) and radiation therapy (RT), was examined in androgen sensitive (LNCaP) and insensitive (PC3) cell lines. Apoptosis was assayed by Caspase 3 + 7 activity and Annexin V binding. AS-PKA significantly increased apoptosis in vitro from RT (both lines), with further increases in LNCaP cells grown in AD medium. In LNCaP cells, AD increased phosphorylated mitogen activated protein-kinase (pMAPK), which was reduced by AS-PKA relative to the mismatch (MM) controls. AS-PKA also reduced pMAPK levels in PC3 cells. Cell death was measured by clonogenic survival assays. In vivo, LNCaP cells were grown orthotopically in nude mice. Tumor kinetics were measured by magnetic resonance imaging and serum prostate-specific antigen. PC3 cells were grown subcutaneously and tumor volume assessed by caliper measurements. In PC3 xenografts, AS-PKA caused a significant increase in tumor doubling time relative to MM controls as a monotherapy or in combination with RT. In orthotopic LNCaP tumors, AS-PKA was ineffective as a monotherapy; however, it caused a statistically significant increase in tumor doubling time relative to MM controls when used in combination with AD, with or without RT. PKARIα levels in tumors were quantified via immunohistochemical (IHC) staining and image analysis. IHC measurements in LNCaP cells exhibited that AS-PKA reduced PKARIα levels in vivo. We demonstrate for the first time that AS-PKA enhances cell killing androgen sensitive prostate cancer cells to AD ± RT and androgen insensitive cells to RT.

AB - The therapeutic efficacy of GemÂ231, a second generation antisense molecule targeted to the RIα subunit of PKARIα (AS-PKA), administered in combination with androgen deprivation (AD) and radiation therapy (RT), was examined in androgen sensitive (LNCaP) and insensitive (PC3) cell lines. Apoptosis was assayed by Caspase 3 + 7 activity and Annexin V binding. AS-PKA significantly increased apoptosis in vitro from RT (both lines), with further increases in LNCaP cells grown in AD medium. In LNCaP cells, AD increased phosphorylated mitogen activated protein-kinase (pMAPK), which was reduced by AS-PKA relative to the mismatch (MM) controls. AS-PKA also reduced pMAPK levels in PC3 cells. Cell death was measured by clonogenic survival assays. In vivo, LNCaP cells were grown orthotopically in nude mice. Tumor kinetics were measured by magnetic resonance imaging and serum prostate-specific antigen. PC3 cells were grown subcutaneously and tumor volume assessed by caliper measurements. In PC3 xenografts, AS-PKA caused a significant increase in tumor doubling time relative to MM controls as a monotherapy or in combination with RT. In orthotopic LNCaP tumors, AS-PKA was ineffective as a monotherapy; however, it caused a statistically significant increase in tumor doubling time relative to MM controls when used in combination with AD, with or without RT. PKARIα levels in tumors were quantified via immunohistochemical (IHC) staining and image analysis. IHC measurements in LNCaP cells exhibited that AS-PKA reduced PKARIα levels in vivo. We demonstrate for the first time that AS-PKA enhances cell killing androgen sensitive prostate cancer cells to AD ± RT and androgen insensitive cells to RT.

KW - androgen deprivation

KW - antisense

KW - prostate cancer

KW - protein kinase A

KW - radiation

UR - http://www.scopus.com/inward/record.url?scp=78650621031&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650621031&partnerID=8YFLogxK

U2 - 10.1002/ijc.25634

DO - 10.1002/ijc.25634

M3 - Article

C2 - 20960462

AN - SCOPUS:78650621031

VL - 128

SP - 962

EP - 973

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 4

ER -